[Clinical evaluation of SM-4300 against bacterial infections in the field of internal medicine].
A new drug of human intact immunoglobulin, SM-4300 was applied to the acute respiratory infections in the field of internal medicine. SM-4300 was administered intravenously for 1 or 3 days at a daily dose of 2.5 g to 4 patients suffering from respiratory infections. We have obtained the results as follows. Clinical effects of SM-4300 were good in 2 cases, fair in 1 case, unknown in 1 case, and no side effects were observed.
D000368:Aged; D001419:Bacteria / Q000276:immunology; D015311:Cefmetazole; D002513:Cephamycins / Q000008:administration & dosage; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D008034:Lincomycin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000628:therapy*
D002513:Cephamycins; D007136:Immunoglobulins; C044640:SM-4300; D015311:Cefmetazole; D008034:Lincomycin